Results 11 to 20 of about 6,366 (244)
The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review
Frontiers in Oncology, 2022 Breast cancer has been reported as the most common cancer in women globally, with 2.26 million new cases in 2020. While anthracyclines are the first-line drug for breast cancer, they cause a variety of adverse reactions and drug resistance, especially ...
Zihan Si +10 more
doaj +1 more source
Pharmacogenomics and regulation of apoptosis in acute myeloid leukaemia [PDF]
Medicinski Podmladak, 2020 Acute myeloid leukaemia (AML) is a heterogenous clonal hematopoietic malignancy primarily treated with combination of cytarabine (ara-C) and anthracyclines. Despite high remission rates, especially in younger patients, a vast majority of patients die due
Pravdić Zlatko +1 more
doaj +1 more source
Cardiotoxic effects of anthracyclines in oncological treatment [PDF]
, 2023 Anthracyclines are antitumor antibiotics used during chemotherapy in cancer patients. Treatment with anthracyclines has good results but a side effect is significant cardiotoxicity.
Tekáčová, Kateřina
core +1 more source
TRP Channels: The Neglected Culprits in Breast Cancer Chemotherapy Resistance?
Membranes, 2023 Breast cancer is a major health concern worldwide, and resistance to therapies remains a significant challenge in treating this disease. In breast cancer, Transient Receptor Potential (TRP) channels are well studied and constitute key players in nearly ...
Mayar Soussi +2 more
doaj +1 more source
Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy
ESC Heart Failure, 2023 Aims This study aims to assess subclinical changes in functional and morphologic myocardial MR parameters very early into a repetitive high‐dose anthracycline treatment (planned cumulative dose >650 mg/m2), which may predict subsequent development of ...
Fabian Muehlberg +6 more
doaj +1 more source
Clinics and Practice, 2021 Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens.
Jukapun Yoodee +5 more
doaj +1 more source
Anthracyclines: biosynthesis, engineering and clinical applications
, 2021 Covering: January 1995 to June 2021 Anthracyclines are glycosylated microbial natural products that harbour potent antiproliferative activities. Doxorubicin has been widely used as an anticancer agent in the clinic for several decades, but its use is ...
Hulst, M.B. +4 more
core +1 more source
Frontiers in Microbiomes, 2023 Breast cancer (BC) is one of the most prevalent cancers worldwide. Fortunately, BC treatment has taken a huge turn in the last few years. Despite these advances, one of the main issues related to systemic treatment remains the management of its side ...
J. Guilherme Gonçalves-Nobre +7 more
doaj +1 more source
BJS (British Journal of Surgery), EarlyView., 2020 This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
Anthracycline Cardiotoxicity in Children [PDF]
New England Journal of Medicine, 2004 More than 70 percent of children who are treated for childhood cancer can be cured. For long-term survivors, possible late effects of treatment and their consequences for the quality of life are a major concern. Cardiotoxic effects of anthracyclines are among the most frequent and serious adverse effects of the treatment of childhood cancer ...
Kremer, L.C.M., Caron, H.N.
openaire +5 more sources